A review of the management of antidepressant discontinuation symptoms

Therapeutic Advances in Psychopharmacology

Volumn 5, Issue 6, 2015, Pages 357-368

  Wilson, Emma ^a   Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antidepressant medication; discontinuation syndrome; gradual dose tapering

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; PAROXETINE; VENLAFAXINE;

COGNITIVE THERAPY; DEPRESSION; DISCONTINUATION SYNDROME; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; MANAGED CARE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REASSURANCE; REVIEW; SIDE EFFECT; TREATMENT WITHDRAWAL;

EID: 84997907902     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125315612334     Document Type: Review

References (56)

1. Baldessarini R. Tondo L. Ghiani C. Lepri B. (2010) Illness risk following rapid versus gradual discontinuation of antidepressant. Am J Psychiatry 167: 934–941.
2. Baldwin D. Montgomery S. Nil R. Lader M. (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10: 73–84.
3. Beier M. Martin C. (2007) Gradual dose reduction and medication tapering: a clinical perspective. Consult Pharm 22: 628–644.
4. Bitter I. Filipovits D. Czobor P. (2011) Adverse reactions to duloxetine in depression. Expert Opin Drug Saf 10: 839–850.
5. Black K. Shea C. Dursun S. Kutcher S. (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25: 255–261.
6. Blier P. Tremblay P. (2006) Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 67(Suppl. 4): 8–13.
7. Chambers C. Johnson K. Dick L. Felix R. Jones K. (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335: 1010–1015.
8. Cleare A. Pariante C. Young A. (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29: 459–525.
9. Cohen L. Altshuler L. Harlow B. Nonacs R. Newport J. Viguera A. et al. (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. J Am Med Assoc 295: 499–507.
10. Coryell W. (2013) Depressive disorders. Merck Manuals Professional Edition. Available at: http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html#v1028131 (accessed 25 August 2014).
11. Cromarty P. Jonsson J. Moorhead S. Freeston M. (2010) Cognitive behaviour therapy for withdrawal from antidepressant medication: a single case series. Behav Cogn Psychother 39: 77–97.
12. Davé S. Classi P. Le T. Maguire A. Ball S. (2012) Discontinuation of antidepressant therapy among patients with major depressive disorder. Open J Psychiatry 2: 272–280.
13. Dodd S. Malhi G. Tiller J. Schweitzer I. Hickie I. Khoo J. et al. (2011) A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry 45: 712–725.
14. Edwards G. (2006) Withdrawing antidepressants: guide to patient management. Prescriber, 5 January 2006.
15. Galbally M. Lewis A. Lum J. Buist A. (2009) Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 43: 846–854.
16. Gartlehner G. Hansen R. Morgan L. Thaler K. Lux L. Van Noord M. et al. (2011) Second-generation antidepressants in the pharmacologic treatment of adult depression. An update of the 2007 comparative effectiveness review. Comparative Effectiveness Reviews No. 46.
17. Goldstein R. Storch E. Lehmkuhl H. Geffken G. Goodman W. Murphy T. (2009) Successful medication withdrawal after cognitive-behavioral therapy in a treatment resistant male with obsessive-compulsive disorder. Depress Anxiety 26: 23–25.
18. Green B. (2011) Focus on agomelatine. Curr Med Res Opin 27: 745–749.
19. Groot P. (2013) Tapering strips for paroxetine and venlafaxine. Tijdschr Psychiatr 55: 789–794.
20. Haddad P. Anderson I. (2007) Recognising and managing antidepressant discontinuation symptoms. APT 13: 447–457.
21. Haddad P. Pal B. Clarke P. Wieck A. Sirdhiran S. (2005) Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol 19: 554–557.
22. Hale T. Kendall-Tackett K. Cong Z. Votta R. McCurdy F. (2010) Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med 5: 283–288.
23. Haw C. Stubbs J. (2010) Patient information leaflets for antidepressants: Are patients getting the information they need? J Affect Disord 128: 165–170.
24. Himei A. Okamura T. (2006) Discontinuation syndrome with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 20: 665–672.
25. Howland R. (2010). Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv 48: 9–12.
26. Joffe R. (2006) Discontinuing treatment for psychiatric disorders. J Psychiatry Neurosci 31: 11–12.
27. Lader M. (2007) Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 67: 1657–1663.
28. Lieberman J. (2003) History of the use of antidepressants in primary care. Primary care companion. J Clin Psychiatry 5: 6–10.
29. Lopez-Peig C. Mundet X. Casabella B. Luis del Val J. Lacasta D. Diogene E. (2012) Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain. BMC Res Notes 5: 684.
30. Marcus M. Yasamy M. van Ommeren M. Chisholm D. Saxena S. (2012) Depression: A Global Health Concern. Available at: http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf (accessed 6 August 2014).
31. McAllister-Williams R. Baldwin D. Haddad P. Bazire S. (2010) The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 25: 95–102.
32. McHugh B. Krishnadas R. (2011) Guide to safely withdrawing antidepressants in primary care. Prescriber, 5 September 2011.
33. Mind (2014) Information and support. http://www.mind.org.uk/information-support/drugs-and-treatments/antidepressants/side-effects-and-coming-off/#.U_2CuNuF9Id (accessed 24 August 2014).
34. Montgomery S. Kennedy S. Burrows G. Lejoyeux M. Hindmarch I. (2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19: 271–280.
35. Muzina D. (2010) Discontinuing an Antidepressant? Tapering tips to ease distressing symptoms. Curr Psychiatry 9: 50–61.
36. Offidani E. Guidi J. Tomba E. Fava G. (2013) Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 82: 355–362.
37. Ogle N. Akkerman S. (2013) Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharmacy Pract 26: 389–396.
38. Phelps J. (2011) Tapering antidepressants: Is three months slow enough? Med Hypotheses 77: 1006–1008.
39. Reeves R. Mack J. Beddingfield J. (2003) Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy 23: 678–681.
40. Reid I. Cameron I. (2009) Depression: Current approaches to management in primary care. Prescriber, 19 February 2009.
41. Renoir T. (2013) Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 16: 45.
42. Rosenbaum J. Fava M. Hoog S. Ascroft R. Krebs W. (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44: 77–87.
43. Schatzberg A. Blier P. Delgado P. Fava M. Haddad P. Shelton R. (2006) Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67: 27–31.
44. Schatzberg A. Haddad P. Kaplan E. Lejoyeux M. Rosenbaum J. Young A. Zajecka J. (1997) Possible mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 58: 23–27.
45. Sheldon R. (2006) The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 67: 3–7.
46. Smeraldi E. Delmonte D. (2013) Agomelatine in depression. Expert Opin Drug Saf 12: 873–880.
47. Spence R. Roberts A. Ariti C. Bardsley M. (2014) Focus on: Antidepressant Prescribing. Trends in the prescribing of antidepressants in primary care. The Health Foundation, Nuffield Trust.
48. Tartakovsky M. (2011) SSRI Discontinuation or Withdrawal Syndrome. Psych Central. Available at: http://psychcentral.com/lib/ssri-discontinuation-or-withdrawal-syndrome/0005734 (7 August 2014).
49. Tint A. Haddad P. Anderson I. (2008) The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 22: 330–333.
50. van Geffen E. Hugtenburg J. Heerdink E. van Hulten R. Egberts A. (2005) Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 61: 303–307.
51. Warner C. Bobo W. Warner C. Reid S. Rachal J. (2006) Antidepressant discontinuation syndrome. Am Fam Physician 1; 74: 449–456.
52. WebMD (2014) Withdrawal from antidepressants. http://www.webmd.com/depression/guide/withdrawal-from-antidepressants (accessed 24 August 2014).
53. Wiese B. (2011) Geriatric depression: The use of antidepressants in the elderly. BCMJ 53: 341–347.
54. Yasui-Furugori N. Kaneko S. (2011) Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 65: 384–385.
55. Zajecka J. Tracy K. Mitchell S. (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 58: 291–297.
56. Zarowitz B. (2006) Antidepressant tapering: avoiding adverse consequences of gradual dose reduction. Geriatr Nurs 28: 75–79.